A double-blind, placebo-controlled, randomized trial of varenicline in hookah tobacco smokers in Pakistan
Background Hookah tobacco smoking has increased worldwide yet there is little evidence for the efficacy of pharmacological therapies to achieve abstinence among hookah smokers. Our objective was to assess the efficacy of varenicline when added to behavioural support for hookah tobacco cessation. Me...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Publishing
2018-03-01
|
| Series: | Tobacco Induced Diseases |
| Subjects: | |
| Online Access: | http://www.journalssystem.com/tid/A-double-blind-placebo-controlled-randomized-trial-of-varenicline-in-hookah-tobacco,84550,0,2.html |
| _version_ | 1818343723175510016 |
|---|---|
| author | Omara Dogar Mona Kanaan Raana Zahid Sonia Mansoor Mohammad Jawad Jasjit S Ahluwalia Kamran Siddiqi |
| author_facet | Omara Dogar Mona Kanaan Raana Zahid Sonia Mansoor Mohammad Jawad Jasjit S Ahluwalia Kamran Siddiqi |
| author_sort | Omara Dogar |
| collection | DOAJ |
| description | Background
Hookah tobacco smoking has increased worldwide
yet there is little evidence for the efficacy of pharmacological therapies to
achieve abstinence among hookah smokers. Our objective was to assess the
efficacy of varenicline when added to behavioural support for hookah tobacco cessation.
Methods
In 2016, we conducted a double-blind, placebo
controlled, randomized trial in Pakistan enrolling 510 daily hookah users who
were willing to quit. All participants received behavioural support and either
varenicline or placebo at randomisation. The primary outcome was 25 weeks
continuous abstinence biochemically verified by a carbon monoxide level of
< 10 ppm.
Results
Among the 510 trial participants, 429 (84%)
were male and 81 (16%) female; 249 (49%) smoked only hookah and 261 (51%) smoked
both hookah and cigarettes. 21 participants withdrew from treatment mainly due
to adverse events. We recently completed the last follow-up (25 weeks) on May
23 rd , 2017 with a 93% (475/510) retention rate. The data will remain
blinded for treatment allocation until the primary analysis is complete. [Trial Flow Chart]
Conclusions
We will report our primary outcome results at the
'17th
World conference on Tobacco or Health' in Cape Town for the first ever trial of varenicline among hookah
smokers. The findings of this pharmacotherapy trial will have major implications
for knowledge translation, practice and policy regarding hookah tobacco use. |
| first_indexed | 2024-12-13T16:35:07Z |
| format | Article |
| id | doaj.art-ba3e7693ce324887beceeea9dc7009a0 |
| institution | Directory Open Access Journal |
| issn | 1617-9625 |
| language | English |
| last_indexed | 2024-12-13T16:35:07Z |
| publishDate | 2018-03-01 |
| publisher | European Publishing |
| record_format | Article |
| series | Tobacco Induced Diseases |
| spelling | doaj.art-ba3e7693ce324887beceeea9dc7009a02022-12-21T23:38:25ZengEuropean PublishingTobacco Induced Diseases1617-96252018-03-0116110.18332/tid/8455084550A double-blind, placebo-controlled, randomized trial of varenicline in hookah tobacco smokers in PakistanOmara Dogar0Mona Kanaan1Raana Zahid2Sonia Mansoor3Mohammad Jawad4Jasjit S Ahluwalia5Kamran Siddiqi6University of York, United KingdomUniversity of York, United KingdomThe Initiative, PakistanThe Initiative, PakistanImperial College London, United KingdomIndependent Consultant, United States of AmericaUniversity of York, United KingdomBackground Hookah tobacco smoking has increased worldwide yet there is little evidence for the efficacy of pharmacological therapies to achieve abstinence among hookah smokers. Our objective was to assess the efficacy of varenicline when added to behavioural support for hookah tobacco cessation. Methods In 2016, we conducted a double-blind, placebo controlled, randomized trial in Pakistan enrolling 510 daily hookah users who were willing to quit. All participants received behavioural support and either varenicline or placebo at randomisation. The primary outcome was 25 weeks continuous abstinence biochemically verified by a carbon monoxide level of < 10 ppm. Results Among the 510 trial participants, 429 (84%) were male and 81 (16%) female; 249 (49%) smoked only hookah and 261 (51%) smoked both hookah and cigarettes. 21 participants withdrew from treatment mainly due to adverse events. We recently completed the last follow-up (25 weeks) on May 23 rd , 2017 with a 93% (475/510) retention rate. The data will remain blinded for treatment allocation until the primary analysis is complete. [Trial Flow Chart] Conclusions We will report our primary outcome results at the '17th World conference on Tobacco or Health' in Cape Town for the first ever trial of varenicline among hookah smokers. The findings of this pharmacotherapy trial will have major implications for knowledge translation, practice and policy regarding hookah tobacco use.http://www.journalssystem.com/tid/A-double-blind-placebo-controlled-randomized-trial-of-varenicline-in-hookah-tobacco,84550,0,2.htmlWCTOH |
| spellingShingle | Omara Dogar Mona Kanaan Raana Zahid Sonia Mansoor Mohammad Jawad Jasjit S Ahluwalia Kamran Siddiqi A double-blind, placebo-controlled, randomized trial of varenicline in hookah tobacco smokers in Pakistan Tobacco Induced Diseases WCTOH |
| title | A double-blind, placebo-controlled, randomized trial of varenicline in hookah tobacco smokers in Pakistan |
| title_full | A double-blind, placebo-controlled, randomized trial of varenicline in hookah tobacco smokers in Pakistan |
| title_fullStr | A double-blind, placebo-controlled, randomized trial of varenicline in hookah tobacco smokers in Pakistan |
| title_full_unstemmed | A double-blind, placebo-controlled, randomized trial of varenicline in hookah tobacco smokers in Pakistan |
| title_short | A double-blind, placebo-controlled, randomized trial of varenicline in hookah tobacco smokers in Pakistan |
| title_sort | double blind placebo controlled randomized trial of varenicline in hookah tobacco smokers in pakistan |
| topic | WCTOH |
| url | http://www.journalssystem.com/tid/A-double-blind-placebo-controlled-randomized-trial-of-varenicline-in-hookah-tobacco,84550,0,2.html |
| work_keys_str_mv | AT omaradogar adoubleblindplacebocontrolledrandomizedtrialofvareniclineinhookahtobaccosmokersinpakistan AT monakanaan adoubleblindplacebocontrolledrandomizedtrialofvareniclineinhookahtobaccosmokersinpakistan AT raanazahid adoubleblindplacebocontrolledrandomizedtrialofvareniclineinhookahtobaccosmokersinpakistan AT soniamansoor adoubleblindplacebocontrolledrandomizedtrialofvareniclineinhookahtobaccosmokersinpakistan AT mohammadjawad adoubleblindplacebocontrolledrandomizedtrialofvareniclineinhookahtobaccosmokersinpakistan AT jasjitsahluwalia adoubleblindplacebocontrolledrandomizedtrialofvareniclineinhookahtobaccosmokersinpakistan AT kamransiddiqi adoubleblindplacebocontrolledrandomizedtrialofvareniclineinhookahtobaccosmokersinpakistan AT omaradogar doubleblindplacebocontrolledrandomizedtrialofvareniclineinhookahtobaccosmokersinpakistan AT monakanaan doubleblindplacebocontrolledrandomizedtrialofvareniclineinhookahtobaccosmokersinpakistan AT raanazahid doubleblindplacebocontrolledrandomizedtrialofvareniclineinhookahtobaccosmokersinpakistan AT soniamansoor doubleblindplacebocontrolledrandomizedtrialofvareniclineinhookahtobaccosmokersinpakistan AT mohammadjawad doubleblindplacebocontrolledrandomizedtrialofvareniclineinhookahtobaccosmokersinpakistan AT jasjitsahluwalia doubleblindplacebocontrolledrandomizedtrialofvareniclineinhookahtobaccosmokersinpakistan AT kamransiddiqi doubleblindplacebocontrolledrandomizedtrialofvareniclineinhookahtobaccosmokersinpakistan |